Date: 2014-03-26
Type of information: Collaboration agreement
Compound:
Company: Genentech, a member of the Roche Group (USA - Switzerland) Xenon Pharmaceuticals (Canada)
Therapeutic area: CNS diseases
Type agreement:
Action mechanism:
Disease: pain
Details: * On March 26, 2014, Xenon Pharmaceuticals has announced the establishment of a new collaboration with Genentech, a member of the Roche Group, for pain genetics, with the goal of discovering and validating new therapeutic targets and mechanisms for treating pain. The collaboration leverages Xenon\'s Extreme Genetics discovery platform to focus on rare phenotypes where individuals have an inability to perceive pain or where individuals have non-precipitated spontaneous severe pain. This new collaboration agreement builds on the strategic alliance established between Xenon and Genentech in 2012 for the discovery and development of compounds and companion diagnostics for the potential treatment of pain.
Pursuant to the terms of the new agreement, both Xenon and Genentech will own the intellectual property arising out of the collaboration. Xenon has also granted Genentech a time-limited, exclusive right of negotiation on a target-by-target basis to form joint drug discovery collaborations. Financial terms of the agreement were not disclosed.
Financial terms:
Latest news:
